Osimertinib

Summary

Osimertinib (CHEMBL3353410) is an approved small-molecule antineoplastic agent (ATC L01EB04) targeting EGFR; indicated across 12 conditions including neoplasm and non-small cell lung carcinoma; with CIViC clinical evidence for 53 variant-indication associations (e.g. EGFR T790M in lung non-small cell carcinoma).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01EB04
• Targets: 1 (EGFR)
• Indications: 12 conditions
• Clinical trials: 232
• Precision-oncology evidence (CIViC): 53 variant–indication associations
• Chemistry: 499.6 Da · C28H33N7O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3353410
Name	Osimertinib
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	71496458
ChEBI	CHEBI:90943
ATC	L01EB04
Molecular formula	C28H33N7O2
Molecular weight	499.6
InChIKey	DUYJMQONPNNFPI-UHFFFAOYSA-N

SMILES: CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC

IUPAC name: N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide

ChEBI definition: A member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-2-(dimethylamino)ethylamino-5-acrylamidophenyl group. Used (as the mesylate salt) for treatment of EGFR T790M mutation positive non-small cell lung cancer.

Pharmacological roles (ChEBI): antineoplastic agent, epidermal growth factor receptor antagonist.

Also known as: Azd-9291, AZD-9291, AZD-9291 FREE BASE, AZD9291, Mereletinib, Osimertinib, Tagrisso, OSIMERTINIB, osimertinib, Osimertinib; Tagrisso, Osimerlinib

Parent form; salt/anhydrous children: CHEMBL3545063, CHEMBL4472934, CHEMBL4741340, CHEMBL4754013, CHEMBL4784911, CHEMBL6068008

Patent coverage: 3,993 distinct patent families (8,898 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 8,509 (96%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
EGFR	epidermal growth factor receptor	Inhibition	6.31	17.5%	P00533

Broader ChEMBL bioactivity targets: 41 (assay-derived). Sample: Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Receptor tyrosine-protein kinase erbB-2, 5-hydroxytryptamine receptor 2B, Cholecystokinin receptor type A, Alpha-2C adrenergic receptor, Insulin receptor, Epidermal growth factor receptor, D(1A) dopamine receptor, Muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 1A.

Bioactivity

ChEMBL activities: 322 potent at pChembl ≥ 5 of 339 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
EGFR	10.7	IC50	0.02	nM	CHEMBL_ACT_22408226
EGFR	10.3	IC50	0.05	nM	CHEMBL_ACT_25098087
EGFR	10.24	IC50	0.06	nM	CHEMBL_ACT_24976287
EGFR	10.22	IC50	0.06	nM	CHEMBL_ACT_22408234
EGFR	9.8	IC50	0.16	nM	CHEMBL_ACT_25891717
EGFR	9.7	IC50	0.2	nM	CHEMBL_ACT_22408242
EGFR	9.7	IC50	0.2	nM	CHEMBL_ACT_22844195
EGFR	9.6	IC50	0.25	nM	CHEMBL_ACT_24976298
EGFR	9.47	IC50	0.34	nM	CHEMBL_ACT_26025788
EGFR	9.43	IC50	0.37	nM	CHEMBL_ACT_26009419
EGFR	9.38	IC50	0.42	nM	CHEMBL_ACT_19310371
EGFR	9.38	IC50	0.41	nM	CHEMBL_ACT_24413820
EGFR	9.37	IC50	0.43	nM	CHEMBL_ACT_22921882
EGFR	9.3	IC50	0.5	nM	CHEMBL_ACT_22844219
EGFR	9.3	IC50	0.5	nM	CHEMBL_ACT_24823398
EGFR	9.3	IC50	0.5	nM	CHEMBL_ACT_24871173
EGFR	9.29	IC50	0.51	nM	CHEMBL_ACT_25891714
EGFR	9.26	IC50	0.55	nM	CHEMBL_ACT_22814393
EGFR	9.26	IC50	0.55	nM	CHEMBL_ACT_26009379
EGFR	9.22	IC50	0.6	nM	CHEMBL_ACT_22782715
EGFR	9.22	IC50	0.6	nM	CHEMBL_ACT_22968057
EGFR	9.21	IC50	0.62	nM	CHEMBL_ACT_23250045
EGFR	9.15	IC50	0.7	nM	CHEMBL_ACT_25094732
EGFR	9.1	IC50	0.8	nM	CHEMBL_ACT_24871227
EGFR	9.1	IC50	0.8	nM	CHEMBL_ACT_25700936
EGFR	9.05	IC50	0.9	nM	CHEMBL_ACT_18299295
EGFR	9.05	IC50	0.9	nM	CHEMBL_ACT_18539745
EGFR	9.05	IC50	0.9	nM	CHEMBL_ACT_25533425
EGFR	9.02	IC50	0.95	nM	CHEMBL_ACT_19310359
EGFR	9	IC50	1	nM	CHEMBL_ACT_18189839

Target pathways

Aggregated over 1 target gene(s): EGFR.

Top Reactome pathways

37 total, by targets touching each:

Pathway	Targets	Genes
Signaling by ERBB2	1	EGFR
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	1	EGFR
Signaling by ERBB4	1	EGFR
SHC1 events in ERBB2 signaling	1	EGFR
PLCG1 events in ERBB2 signaling	1	EGFR
PIP3 activates AKT signaling	1	EGFR
Signaling by EGFR	1	EGFR
GRB2 events in EGFR signaling	1	EGFR
GAB1 signalosome	1	EGFR
SHC1 events in EGFR signaling	1	EGFR
EGFR downregulation	1	EGFR
GRB2 events in ERBB2 signaling	1	EGFR
PI3K events in ERBB2 signaling	1	EGFR
EGFR interacts with phospholipase C-gamma	1	EGFR
EGFR Transactivation by Gastrin	1	EGFR
Constitutive Signaling by Aberrant PI3K in Cancer	1	EGFR
Signal transduction by L1	1	EGFR
Constitutive Signaling by EGFRvIII	1	EGFR
Inhibition of Signaling by Overexpressed EGFR	1	EGFR
RAF/MAP kinase cascade	1	EGFR
ERBB2 Regulates Cell Motility	1	EGFR
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	1	EGFR
ERBB2 Activates PTK6 Signaling	1	EGFR
Cargo recognition for clathrin-mediated endocytosis	1	EGFR
Clathrin-mediated endocytosis	1	EGFR
PTK6 promotes HIF1A stabilization	1	EGFR
Downregulation of ERBB2 signaling	1	EGFR
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	1	EGFR
Extra-nuclear estrogen signaling	1	EGFR
NOTCH3 Activation and Transmission of Signal to the Nucleus	1	EGFR

Dominant GO biological processes

GO term	Targets
cell morphogenesis	1
ossification	1
embryonic placenta development	1
positive regulation of protein phosphorylation	1
hair follicle development	1
ubiquitin-dependent protein catabolic process	1
signal transduction	1
cell surface receptor signaling pathway	1
epidermal growth factor receptor signaling pathway	1
salivary gland morphogenesis	1
learning or memory	1
positive regulation of cell population proliferation	1
gene expression	1
protein ubiquitination	1
cerebral cortex cell migration	1

Indications & clinical

Indications

12 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
lung neoplasm	3	MONDO:0021117	MONDO:0008903
adenocarcinoma	2	MONDO:0004970	EFO:0000228
squamous cell carcinoma	2	MONDO:0005096	EFO:0000707
carcinoma	2	MONDO:0004993	EFO:0000313
glioblastoma	2	MONDO:0018177	EFO:0000519
colorectal neoplasm	2	MONDO:0005335	MONDO:0005575
brain neoplasm	1	MONDO:0021211	EFO:0003833

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 232.

Phase distribution

Phase	Trials
PHASE2	97
PHASE1	43
PHASE3	32
PHASE1/PHASE2	28
Not specified	23
PHASE4	4
PHASE2/PHASE3	3
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04413201	PHASE4	ACTIVE_NOT_RECRUITING	AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC
NCT07279935	PHASE4	NOT_YET_RECRUITING	Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.
NCT03853551	PHASE4	COMPLETED	Osimertinib Study in Indian Patients
NCT05785208	PHASE4	UNKNOWN	Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.
NCT02411448	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
NCT02511106	PHASE3	ACTIVE_NOT_RECRUITING	AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
NCT03521154	PHASE3	ACTIVE_NOT_RECRUITING	A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
NCT04035486	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
NCT04181060	PHASE3	RECRUITING	Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
NCT04351555	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
NCT04487080	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04695925	PHASE3	ACTIVE_NOT_RECRUITING	Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations
NCT04765059	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
NCT05020769	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.
NCT05120349	PHASE3	ACTIVE_NOT_RECRUITING	A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
NCT05261399	PHASE3	ACTIVE_NOT_RECRUITING	Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
NCT05382728	PHASE3	RECRUITING	Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
NCT05624996	PHASE3	RECRUITING	Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NCT05629234	PHASE3	ACTIVE_NOT_RECRUITING	Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
NCT06323148	PHASE3	NOT_YET_RECRUITING	Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)
NCT06350097	PHASE3	RECRUITING	Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06380348	PHASE3	NOT_YET_RECRUITING	JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations
NCT06417814	PHASE3	RECRUITING	A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06486142	PHASE3	RECRUITING	EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study
NCT06670196	PHASE3	RECRUITING	A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06735391	PHASE3	RECRUITING	A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
NCT06838273	PHASE3	RECRUITING	A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)
NCT07005102	PHASE2/PHASE3	RECRUITING	A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07376382	PHASE3	NOT_YET_RECRUITING	A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC
NCT02454933	PHASE3	COMPLETED	Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours
NCT02474355	PHASE3	COMPLETED	Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC
NCT02959749	PHASE2/PHASE3	COMPLETED	Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
NCT02997501	PHASE3	COMPLETED	T790M Plasma Testing Methodology Comparison and Clinical Validation
NCT04816214	PHASE3	TERMINATED	Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy
NCT04870190	PHASE3	UNKNOWN	Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
NCT05015608	PHASE3	COMPLETED	Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification
NCT05104281	PHASE3	UNKNOWN	Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer
NCT05493501	PHASE3	TERMINATED	Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
NCT06093503	PHASE3	WITHDRAWN	Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
NCT02465060	PHASE2	ACTIVE_NOT_RECRUITING	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Clinical evidence (CIViC)

Variant × indication × effect (53 predictive associations from 59 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
EGFR T790M	Lung Non-small Cell Carcinoma	Sensitivity/Response	Osimertinib	CIViC A	EID1592 +4
EGFR L858R OR EGFR Exon 19 Deletion	Lung Non-small Cell Carcinoma	Sensitivity/Response	Osimertinib	CIViC A	EID11219 +1
EGFR L858R AND EGFR T790M	Lung Non-small Cell Carcinoma	Sensitivity/Response	Osimertinib	CIViC A	EID11599
EGFR L858R OR EGFR Exon 19 Deletion	Lung Non-small Cell Carcinoma	Sensitivity/Response	Chemotherapy + Osimertinib	CIViC A	EID12015
EGFR T790M AND EGFR Exon 19 Deletion	Lung Non-small Cell Carcinoma	Sensitivity/Response	Osimertinib	CIViC A	EID11598
EGFR Exon 20 Insertion	Lung Non-small Cell Carcinoma	Sensitivity/Response	Osimertinib	CIViC B	EID7610
EGFR G719	Lung Non-small Cell Carcinoma	Sensitivity/Response	Osimertinib	CIViC B	EID7857
EGFR L861Q	Lung Non-small Cell Carcinoma	Sensitivity/Response	Osimertinib	CIViC B	EID7858
EGFR S768I	Lung Non-small Cell Carcinoma	Sensitivity/Response	Osimertinib	CIViC B	EID7859
ERBB2 Activating Mutation OR ERBB2 T790M	Cancer	Sensitivity/Response	Osimertinib	CIViC B	EID12026
EGFR C797S	Lung Non-small Cell Carcinoma	Resistance	Osimertinib	CIViC B	EID964
EGFR::RAD51 Fusion	Lung Adenocarcinoma	Sensitivity/Response	Osimertinib	CIViC C	EID11021 +1
EGFR A763_Y764insFQEA	Lung Non-small Cell Carcinoma	Sensitivity/Response	Osimertinib	CIViC C	EID9225
EGFR A767_V769dupASV	Lung Non-small Cell Carcinoma	Sensitivity/Response	Osimertinib	CIViC C	EID9220
EGFR Amplification OR EGFR VIII	Malignant Glioma	Sensitivity/Response	Osimertinib	CIViC C	EID12694
EGFR D770_N771insG	Lung Non-small Cell Carcinoma	Sensitivity/Response	Osimertinib	CIViC C	EID9223
EGFR Exon 19 Deletion AND MET Y1003N	Lung Adenocarcinoma	Sensitivity/Response	Osimertinib + Capmatinib	CIViC C	EID11418
EGFR L858R	Lung Adenocarcinoma	Sensitivity/Response	Osimertinib	CIViC C	EID8053
EGFR L858R AND EGFR T790M AND VOPP1::EGFR Fusion	Lung Adenocarcinoma	Sensitivity/Response	Osimertinib	CIViC C	EID12549
EGFR N771_P772insL	Lung Non-small Cell Carcinoma	Sensitivity/Response	Osimertinib	CIViC C	EID9221
EGFR S768_D770dup	Lung Non-small Cell Carcinoma	Sensitivity/Response	Osimertinib	CIViC C	EID9224
EGFR T790M	Lung Squamous Cell Carcinoma	Sensitivity/Response	Osimertinib	CIViC C	EID12066
EGFR T790M	Lung Adenocarcinoma	Sensitivity/Response	Osimertinib	CIViC C	EID2157
EGFR T790M	Pancreatic Adenocarcinoma	Sensitivity/Response	Osimertinib	CIViC C	EID6006
EGFR T790M AND EGFR Exon 19 Deletion	Lung Adenocarcinoma	Sensitivity/Response	Osimertinib	CIViC C	EID1397
EGFR T790M AND EGFR Exon 19 Deletion AND MET Splice Site (c.3027_3028+21delAGGTATATTTCAGTTTATTGTTC	Lung Adenocarcinoma	Sensitivity/Response	Capmatinib + Osimertinib	CIViC C	EID11693
EGFR T790M AND EGFR Exon 19 del	Lung Adenocarcinoma	Sensitivity/Response	Osimertinib	CIViC C	EID12946
EGFR::ERBB4 Fusion	Lung Adenocarcinoma	Sensitivity/Response	Osimertinib + Mobocertinib + Trastuzumab Deruxtecan + Tarloxotinib	CIViC C	EID12373
EGFR::RAD51 Fusion	Lung Adenocarcinoma	Sensitivity/Response	Osimertinib + Erlotinib	CIViC C	EID12370
ERBB2 L755P	Lung Non-small Cell Carcinoma	Sensitivity/Response	Osimertinib	CIViC C	EID12107

+23 more predictive associations (showing top 30 by level).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 13 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

156 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
AFATINIB	ChEMBL + PubChem	Phase 4 (approved)	EGFR
SELUMETINIB	ChEMBL + PubChem	Phase 4 (approved)	EGFR
ABEMACICLIB	ChEMBL	Phase 4 (approved)	EGFR
ACALABRUTINIB	ChEMBL	Phase 4 (approved)	EGFR
AFATINIB DIMALEATE	ChEMBL	Phase 4 (approved)	EGFR
ALECTINIB	ChEMBL	Phase 4 (approved)	EGFR
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	EGFR
AXITINIB	ChEMBL	Phase 4 (approved)	EGFR
BACITRACIN	ChEMBL	Phase 4 (approved)	EGFR
BITHIONOL	ChEMBL	Phase 4 (approved)	EGFR
BOSUTINIB	ChEMBL	Phase 4 (approved)	EGFR
BRIGATINIB	ChEMBL	Phase 4 (approved)	EGFR
CABOZANTINIB	ChEMBL	Phase 4 (approved)	EGFR
CERITINIB	ChEMBL	Phase 4 (approved)	EGFR
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	EGFR
CHROMIC CHLORIDE	ChEMBL	Phase 4 (approved)	EGFR
CISPLATIN	ChEMBL	Phase 4 (approved)	EGFR
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	EGFR
COLISTIN	ChEMBL	Phase 4 (approved)	EGFR
CRIZOTINIB	ChEMBL	Phase 4 (approved)	EGFR
DACOMITINIB	ChEMBL	Phase 4 (approved)	EGFR
DASATINIB	ChEMBL	Phase 4 (approved)	EGFR
DOBUTAMINE	ChEMBL	Phase 4 (approved)	EGFR
DOCETAXEL	ChEMBL	Phase 4 (approved)	EGFR
EBASTINE	ChEMBL	Phase 4 (approved)	EGFR
ECONAZOLE	ChEMBL	Phase 4 (approved)	EGFR
ERLOTINIB	ChEMBL	Phase 4 (approved)	EGFR
FEDRATINIB	ChEMBL	Phase 4 (approved)	EGFR
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	EGFR
GEFITINIB	ChEMBL	Phase 4 (approved)	EGFR
GENTIAN VIOLET	ChEMBL	Phase 4 (approved)	EGFR
GILTERITINIB	ChEMBL	Phase 4 (approved)	EGFR
HEXACHLOROPHENE	ChEMBL	Phase 4 (approved)	EGFR
IBRUTINIB	ChEMBL	Phase 4 (approved)	EGFR
IMATINIB	ChEMBL	Phase 4 (approved)	EGFR
LAPATINIB	ChEMBL	Phase 4 (approved)	EGFR
LAPATINIB DITOSYLATE	ChEMBL	Phase 4 (approved)	EGFR
LAZERTINIB	ChEMBL	Phase 4 (approved)	EGFR
LEVODOPA	ChEMBL	Phase 4 (approved)	EGFR
LORLATINIB	ChEMBL	Phase 4 (approved)	EGFR
METHYLDOPA	ChEMBL	Phase 4 (approved)	EGFR
MICONAZOLE	ChEMBL	Phase 4 (approved)	EGFR
MIDOSTAURIN	ChEMBL	Phase 4 (approved)	EGFR
MITOXANTRONE	ChEMBL	Phase 4 (approved)	EGFR
MOBOCERTINIB	ChEMBL	Phase 4 (approved)	EGFR
MONTELUKAST	ChEMBL	Phase 4 (approved)	EGFR
NELFINAVIR	ChEMBL	Phase 4 (approved)	EGFR
NERATINIB	ChEMBL	Phase 4 (approved)	EGFR
NICLOSAMIDE	ChEMBL	Phase 4 (approved)	EGFR
OLMUTINIB	ChEMBL	Phase 4 (approved)	EGFR
PERHEXILINE	ChEMBL	Phase 4 (approved)	EGFR
PONATINIB	ChEMBL	Phase 4 (approved)	EGFR
SORAFENIB	ChEMBL	Phase 4 (approved)	EGFR
SULOCTIDIL	ChEMBL	Phase 4 (approved)	EGFR
SUNITINIB	ChEMBL	Phase 4 (approved)	EGFR
TAMOXIFEN	ChEMBL	Phase 4 (approved)	EGFR
TERFENADINE	ChEMBL	Phase 4 (approved)	EGFR
THIORIDAZINE	ChEMBL	Phase 4 (approved)	EGFR
TRIBROMSALAN	ChEMBL	Phase 4 (approved)	EGFR
TUCATINIB	ChEMBL	Phase 4 (approved)	EGFR